Zydus Cadila gets FDA approval for Fluphenazine Hydrochloride Tablets
Cadila Healthcare (also known as Zydus Cadila) said that it has secured final approval from the US Food and Drug Administration (FDA) to market Fluphenazine ... Read More
Novartis to expand neuroscience portfolio with $770m acquisition of Cadent Therapeutics
In a bold move to strengthen its neuroscience division, Swiss pharmaceutical giant Novartis has agreed to acquire Cadent Therapeutics, a US-based neuroscience company, in a ... Read More
Biogen strikes $600m deal with Pfizer for promising schizophrenia drug
Biogen, a leading US biotechnology firm, has reached a significant agreement to acquire Pfizer's neurology drug candidate, PF-04958242, which is being developed to address cognitive ... Read More